Article Text

Download PDFPDF
CP-109 Evaluation of clinical, economic and organisational impacts of pharmacists’ interventions on immunosuppressive therapy management among lung transplant outpatients
  1. M Duwez1,
  2. S Chanoine1–3,
  3. M Lepelley4,
  4. TH Vo2,
  5. R Mazet1,3,
  6. B Allenet1–3,
  7. B Camara5,
  8. P Bedouch1–3
  1. 1CHU Grenoble Alpes, Pôle Pharmacie, F-38000 Grenoble, France
  2. 2Université Grenoble Alpes, CNRS-TIMC-IMAG UMR5525/ThEMAS, F-38041 Grenoble, France
  3. 3Université Grenoble Alpes, Faculté de Pharmacie, F-38000 Grenoble, France
  4. 4CHU Grenoble Alpes, Centre Régional de Pharmacovigilance, F-38000 Grenoble, France
  5. 5CHU Grenoble Alpes, Clinique de Pneumologie, F-38000 Grenoble, France


Background Lung transplant recipients require multidisciplinary care because of the complexity of therapeutic management. Clinical pharmacists are able to detect drug related problems (DRPs) and provide recommendations to physicians. The potential significance of pharmacists’ interventions (PIs) has never been studied by a multidimensional approach in lung transplantation (LT).

Purpose We aimed to assess the clinical, economic and organisational impact of PIs on immunosuppressive management among lung transplant outpatients.

Material and methods In our centre, PIs are comprehensively and prospectively collected on Act-IP database, a free access website observatory created by the French Society of Clinical Pharmacy (SFPC) from 2009 onward. Each PI includes patient features, a description of the DRP and the PI according to the SFPC classification. A retrospective analysis of the PIs was performed from 1 January 2009 to 31 December 2015 by an expert committee including a clinical pharmacist, pharmacovigilant and pneumologist. The impact of accepted PIs was assessed according to the validated multidimensional ‘CLEO’ scale, which includes three dimensions: CLinical (harmful, null, minor, moderate, major, lethal, non-determined), Economic (cost increase, no change, cost decrease, not determined) and Organisational impacts (unfavourable, null, favourable, not determined).

Results Among the 1568 PIs performed over the 7 year period, 713 (45.5%) were related to immunosuppressive therapy for which the physician’s acceptance rate was 94.0%. The expert committee considered the clinical impact of PIs as major, moderate and minor in 9.6%, 67.0% and 22.8%, respectively. Major clinical impact was mainly related to drug–drug interactions between immunosuppressants and antifungals (56.0%). Wrong dose was the main cause of moderate clinical impact (75.0%). While 41.6% of PIs led to a cost increase due to dose increase or adding of drug monitoring, 44.8% of PIs helped a cost decrease due to dose decrease or drug discontinuation (44.8%). Most PIs did not have an organisational impact for healthcare professionals (99.1%).

Conclusion This is the first study which has evaluated the clinical, economic and organisational impacts of PIs in lung transplant outpatients. Our findings show that clinical pharmacists play a key role in optimising immunosuppressive therapy management in LT. As experts in drug therapy, clinical pharmacists are able to detect and resolve DRPs to improve patient care.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.